232 related articles for article (PubMed ID: 26753559)
1. Determining optimal prostate-specific antigen thresholds to identify an increased 4-year risk of prostate cancer development: an analysis within the Veterans Affairs Health Care System.
Sutton SS; Crawford ED; Moul JW; Hardin JW; Kruep E
World J Urol; 2016 Aug; 34(8):1107-13. PubMed ID: 26753559
[TBL] [Abstract][Full Text] [Related]
2. Racial differences in the PSA bounce in predicting prostate cancer outcomes after brachytherapy: Evidence from the Department of Veterans Affairs.
Slade AN; Dahman B; Chang MG
Brachytherapy; 2020; 19(1):6-12. PubMed ID: 31611160
[TBL] [Abstract][Full Text] [Related]
3. Racial and Ethnic Disparities in Prostate Cancer Outcomes in the Veterans Affairs Health Care System.
Yamoah K; Lee KM; Awasthi S; Alba PR; Perez C; Anglin-Foote TR; Robison B; Gao A; DuVall SL; Katsoulakis E; Wong YN; Markt SC; Rose BS; Burri R; Wang C; Aboiralor O; Fink AK; Nickols NG; Lynch JA; Garraway IP
JAMA Netw Open; 2022 Jan; 5(1):e2144027. PubMed ID: 35040965
[TBL] [Abstract][Full Text] [Related]
4. Probability of an abnormal screening prostate-specific antigen result based on age, race, and prostate-specific antigen threshold.
Espaldon R; Kirby KA; Fung KZ; Hoffman RM; Powell AA; Freedland SJ; Walter LC
Urology; 2014 Mar; 83(3):599-605. PubMed ID: 24439009
[TBL] [Abstract][Full Text] [Related]
5. Prostate-specific antigen 1.5-4.0 ng/mL: a diagnostic challenge and danger zone.
Crawford ED; Moul JW; Rove KO; Pettaway CA; Lamerato LE; Hughes A
BJU Int; 2011 Dec; 108(11):1743-9. PubMed ID: 21711431
[TBL] [Abstract][Full Text] [Related]
6. The Relationship of Baseline Prostate Specific Antigen and Risk of Future Prostate Cancer and Its Variance by Race.
Verges DP; Dani H; Sterling WA; Weedon J; Atallah W; Mehta K; Schreiber D; Weiss JP; Karanikolas NT
J Natl Med Assoc; 2017 Spring; 109(1):49-54. PubMed ID: 28259216
[TBL] [Abstract][Full Text] [Related]
7. Prostate-specific antigen concentration in young men: new estimates and review of the literature.
Sutcliffe S; Pakpahan R; Sokoll LJ; Elliott DJ; Nevin RL; Cersovsky SB; Walsh PC; Platz EA
BJU Int; 2012 Dec; 110(11):1627-35. PubMed ID: 22502603
[TBL] [Abstract][Full Text] [Related]
8. Association of Prostate-Specific Antigen Velocity With Clinical Progression Among African American and Non-Hispanic White Men Treated for Low-Risk Prostate Cancer With Active Surveillance.
Nelson TJ; Javier-DesLoges J; Deka R; Courtney PT; Nalawade V; Mell L; Murphy J; Parsons JK; Rose BS
JAMA Netw Open; 2021 May; 4(5):e219452. PubMed ID: 33999164
[TBL] [Abstract][Full Text] [Related]
9. Prostate-specific antigen (PSA) and PSA density: racial differences in men without prostate cancer.
Henderson RJ; Eastham JA; Culkin DJ; Kattan MW; Whatley T; Mata J; Venable D; Sartor O
J Natl Cancer Inst; 1997 Jan; 89(2):134-8. PubMed ID: 8998182
[TBL] [Abstract][Full Text] [Related]
10. Do racial disparities exist in the use of prostate cancer screening and detection tools in veterans?
Hudson MA; Luo S; Chrusciel T; Yan Y; Grubb RL; Carson K; Scherrer JF
Urol Oncol; 2014 Jan; 32(1):34.e9-18. PubMed ID: 23506962
[TBL] [Abstract][Full Text] [Related]
11. African-American men with prostate cancer have larger tumor volume than Caucasian men despite no difference in serum prostate specific antigen.
Fuletra JG; Kamenko A; Ramsey F; Eun DD; Reese AC
Can J Urol; 2018 Feb; 25(1):9193-9198. PubMed ID: 29524974
[TBL] [Abstract][Full Text] [Related]
12. Pathological and Biochemical Outcomes among African-American and Caucasian Men with Low Risk Prostate Cancer in the SEARCH Database: Implications for Active Surveillance Candidacy.
Leapman MS; Freedland SJ; Aronson WJ; Kane CJ; Terris MK; Walker K; Amling CL; Carroll PR; Cooperberg MR
J Urol; 2016 Nov; 196(5):1408-1414. PubMed ID: 27352635
[TBL] [Abstract][Full Text] [Related]
13. The association between presentation PSA and race in two sequential time periods in prostate cancer patients seen at a university hospital and its community affiliates.
Pan CC; Lee JS; Chan JL; Sandler HM; Underwood W; McLaughlin PW
Int J Radiat Oncol Biol Phys; 2003 Dec; 57(5):1292-6. PubMed ID: 14630264
[TBL] [Abstract][Full Text] [Related]
14. Baseline Prostate-specific Antigen Level in Midlife and Aggressive Prostate Cancer in Black Men.
Preston MA; Gerke T; Carlsson SV; Signorello L; Sjoberg DD; Markt SC; Kibel AS; Trinh QD; Steinwandel M; Blot W; Vickers AJ; Lilja H; Mucci LA; Wilson KM
Eur Urol; 2019 Mar; 75(3):399-407. PubMed ID: 30237027
[TBL] [Abstract][Full Text] [Related]
15. Earlier prostate-specific antigen testing in African American men--Clinical support for the recommendation.
Saltzman AF; Luo S; Scherrer JF; Carson KD; Grubb RL; Hudson MA
Urol Oncol; 2015 Jul; 33(7):330.e9-17. PubMed ID: 25937424
[TBL] [Abstract][Full Text] [Related]
16. Initial prostate specific antigen 1.5 ng/ml or greater in men 50 years old or younger predicts higher prostate cancer risk.
Tang P; Sun L; Uhlman MA; Robertson CN; Polascik TJ; Albala DM; Donatucci CF; Moul JW
J Urol; 2010 Mar; 183(3):946-50. PubMed ID: 20083275
[TBL] [Abstract][Full Text] [Related]
17. African-American race is a predictor of prostate cancer detection: incorporation into a pre-biopsy nomogram.
Yanke BV; Carver BS; Bianco FJ; Simoneaux WJ; Venable DD; Powell IJ; Eastham JA
BJU Int; 2006 Oct; 98(4):783-7. PubMed ID: 16978273
[TBL] [Abstract][Full Text] [Related]
18. Prostate Specific Antigen-Growth Curve Model to Predict High-Risk Prostate Cancer.
Shoaibi A; Rao GA; Cai B; Rawl J; Haddock KS; Hébert JR
Prostate; 2017 Feb; 77(2):173-184. PubMed ID: 27699819
[TBL] [Abstract][Full Text] [Related]
19. Prostate-specific antigen-based risk-adapted discontinuation of prostate cancer screening in elderly African American and Caucasian American men.
Tang P; Sun L; Uhlman MA; Robertson CN; Polascik TJ; Albala DM; Donatucci CF; Moul JW
Urology; 2010 Nov; 76(5):1058-62. PubMed ID: 20035982
[TBL] [Abstract][Full Text] [Related]
20. Prostate-specific antigen values at the time of prostate cancer diagnosis in African-American men.
Moul JW; Sesterhenn IA; Connelly RR; Douglas T; Srivastava S; Mostofi FK; McLeod DG
JAMA; 1995 Oct; 274(16):1277-81. PubMed ID: 7563532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
